Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing.
Aspect to receive 75 million US dollars in initial payments and up to 650 million dollars in future milestone payments per product arising from the collaboration, plus tiered royalties.
https://finance.yahoo.com/news/aspect-biosystems-novo-nordisk-enter-085800247.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.